Par Pharmaceutical Companies, Inc.  

(Public, NYSE:PRX)   Watch this stock  
Find more results for Par Pharmaceutical Companies, Inc
- Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 2.04
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -11.20% -9.65%
Operating margin -9.78% -6.63%
EBITD margin - 24.58%
Return on average assets -4.95% -3.87%
Return on average equity -26.14% -17.76%
Employees 819 -
CDP Score - -


300 Tice Boulevard
United States - Map
+1-201-8024000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.

Officers and directors

Paul V. Campanelli Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Michael A. Tropiano Chief Financial Officer, Executive Vice President, Director
Age: 56
Bio & Compensation  - Reuters
Terrance John Coughlin Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Thomas J. Haughey Chief Administrative Officer, General Counsel, Director
Age: 50
Bio & Compensation  - Reuters